Professor John Chapman (Pitié-Salpètriére University Hospital, and Sorbonne University, Paris, France) discusses how insights from 'OMICS' technologies into cardiometabolic phenotype could aid clinical decision making in lipid management.

Read the report »

Professor Gaetano De Ferrari: How can we optimise the use of PCSK9 inhibition?

Watch the video here »

Dr Pia Kamstrup: Does lowering lipoprotein(a) matter when LDL cholesterol is very low?

Watch the video here »

Professor Derick Raal: Beyond PCSK9 monoclonal antibodies – what's in the PCSK9 pipeline?

Watch the video here »

Professor Raul Santos: Do we need to consider more than coronary complications in familial hypercholesterolaemia?

Watch the video here »